Compilation Instructions for Expert Consensus on Clinical Application of Yifei Zhike Capsules
10.13422/j.cnki.syfjx.20252295
- VernacularTitle:《益肺止咳胶囊临床应用专家共识》编制说明
- Author:
Xin LI
1
;
Hongchun ZHANG
2
;
Xuefeng YU
3
;
Weiwei GUO
4
;
Chengjun BAN
5
;
Zhifei WANG
1
;
Yuanyuan LI
1
;
Yingjie ZHI
1
;
Xin CUI
1
;
Yanming XIE
1
Author Information
1. Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. China-Japan Friendship Hospital，Beijing 100029，China
3. The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine，Shenyang 110034，China
4. Qiandongnan Institute of Ethnic Medicine and Affiliated Miao Hospital，Guizhou 556099，China
5. Dongzhimen Hospital， Beijing University of Chinese Medicine，Beijing 101121，China
- Publication Type:Journal Article
- Keywords:
Yifei Zhike capsules;
Miao medicine;
expert consensus;
clinical application;
compilation instructions
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(18):143-148
- CountryChina
- Language:Chinese
-
Abstract:
The compilation instructions for the Expert Consensus on Clinical Application of Yifei Zhike Capsules systematically expound the development background， methodological framework， and core achievements of this consensus. In view of the problems existing in the clinical application of Yifei Zhike Capsules， such as insufficient efficacy evidence and lack of standardized syndrome differentiation， the Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences took the lead and collaborated with 21 tertiary grade-A hospitals and research institutions across China to form a multidisciplinary expert group （comprising 30 experts in clinical medicine， pharmacy， and methodology）. The compilation work was carried out in strict accordance with the World Health Organization （WHO） guidelines， the GB/T 1.1-2020 standard， and the writing specifications for the explanatory notes of expert consensus on clinical application of Chinese patent medicines. Through systematic literature retrieval （including 32 studies， with 24 clinical studies）， Grading of Recommendations Assessment， Development and Evaluations （GRADE）-based evidence grading， and multiple rounds of discussions using the nominal group method （25 experts voted to determine 17 clinical questions）， 5 evidence-based recommendations and 11 expert consensus suggestions were formed. It is clarified that this medicine （Yifei Zhike Capsules） is applicable to the treatment of expectoration/hemoptysis in acute and chronic bronchitis and the adjuvant treatment of pulmonary tuberculosis. It is recommended that it can be used alone or in combination with anti-tuberculosis drugs. The safety evaluation shows that this medicine mainly induces the following adverse reactions： mild gastrointestinal reactions （such as nausea and abdominal pain） and rashes. The contraindicated populations include pregnant women and women during menstruation. The compilation process of the consensus underwent three rounds of expert letter reviews， two rounds of peer reviews， and quality control assessments to ensure methodological rigor and clinical applicability. In addition， through policy alignment， academic promotion， and a dynamic revision mechanism， the standardization of clinical application was promoted， providing a demonstration for the evidence-based transformation of characteristic therapies of Miao medicine.
